西咪替丁与多替拉韦对OCT2和MATE1/2K内源性DDI生物标志物的影响
西咪替丁(400/800 mg)和多替拉韦(50 mg bid)分别主要抑制MATE1/2K和OCT2,二甲双胍CLr分别降低15.5%/42.5%和26.8%/56.9%。1-NMN和m1A的CLrR变化与二甲双胍CLrR正相关,提示其较肌酐更有前景。
要点
- 1-NMN和m1A的CLrR变化与二甲双胍CLrR正相关,可作为OCT2/MATE1/2K的定量生物标志物。
- 肌酐CLr仅在西咪替丁800 mg时显著下降,敏感性不及1-NMN和m1A。
- 西咪替丁和多替拉韦对二甲双胍CLr的抑制程度呈剂量/给药次数依赖。
核心结论
- 1-NMN和m1A可能比肌酐更有前景,用于基于CLrR变化定量评估研究药物对OCT2和MATE1/2K的DDI潜力。
主要发现
- 二甲双胍CLr被西咪替丁400和800 mg分别降低15.5%和42.5%,被多替拉韦首次和第五次给药分别降低26.8%和56.9%。
- 1-NMN的CLrR在西咪替丁400和800 mg分别为0.93和0.64,在多替拉韦首次和第五次给药分别为0.87和0.47。
- m1A的CLrR在西咪替丁400和800 mg分别为1.0和0.80,在多替拉韦首次和第五次给药分别为0.77和0.71。
- 肌酐CLr仅被西咪替丁800 mg显著降低。
- 1-NMN和m1A的个体CLrR与二甲双胍CLrR正相关,r²分别为0.58和0.55。
关键数值与推荐
- 西咪替丁期间m1A与二甲双胍CLrR相关性r²为0.64,优于1-NMN的0.36。
- 多替拉韦期间1-NMN与二甲双胍CLrR相关性r²为0.80,优于m1A的0.32。
临床怎么用
- 临床药学可关注1-NMN和m1A作为OCT2/MATE1/2K介导DDI的早期探索性生物标志物,用于新药DDI风险评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study was designed to assess the quantitative performance of endogenous drug-drug interaction (DDI) biomarkers (N1-methylnicotinamide (1-NMN), N1-methyladenosine (m1A), and creatinine) for the organic cation transporters, OCT2 and MATE1/2K in the kidney. Ten healthy volunteers received cimetidine (400 and 800 mg, single dose) or dolutegravir (50 mg, twice a day) together with metformin (500 mg). Cimetidine and dolutegravir were considered to act mainly as MATE1/2K and OCT2 inhibitors, respectively. The renal clearance (CLr) of metformin was decreased by 15.5% and 42.5% by cimetidine 400 and 800 mg, and by 26.8% and 56.9% by dolutegravir first and fifth doses, respectively. CLr ratio (CLrR) of 1-NMN were 0.93 and 0.64 for cimetidine 400 and 800 mg, and 0.87 and 0.47 for dolutegravir first and fifth doses, respectively. CLrR of m1A was less than that of 1-NMN: 1.0 and 0.80 for cimetidine 400 and 800 mg, and 0.77 and 0.71 for dolutegravir first and fifth doses, respectively. CLr of creatinine was significantly decreased only by cimetidine 800 mg. Individual CLrR of 1-NMN and m1A showed a positive correlation with the corresponding CLrR of metformin with r2 of 0.58 and 0.55, respectively. When evaluated individually, m1A showed a better correlation during cimetidine periods (r2 0.64) than 1-NMN (r2 0.36), but vice versa during dolutegravir periods (r2 1-NMN, 0.80; m1A, 0.32). These results suggest that 1-NMN and m1A might be more promising than creatinine as endogenous biomarkers for quantitatively assessing the DDI potential of investigational drugs for OCT2 and MATE1/2K based on their CLrR change.
引用
- Koishikawa T, Fujiwara K, Taskar K, et al. Effects of Cimetidine and Dolutegravir on the Endogenous Drug-Drug Interaction Biomarkers for Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Protein 1 in Healthy Volunteers. Clin Pharmacol Ther. 2024. PMID: 39497599. doi:10.1002/cpt.3482
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。